|
Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) DCF Valuation |
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Mayinglong Pharmaceutical Group Co., LTD. (600993.SS) Bundle
Looking to assess the intrinsic value of Mayinglong Pharmaceutical Group Co., LTD.? Our (600993SS) DCF Calculator integrates real-world data with comprehensive customization features, enabling you to refine your forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,705.4 | 2,791.6 | 3,385.1 | 3,532.4 | 3,136.7 | 3,274.7 | 3,418.8 | 3,569.2 | 3,726.2 | 3,890.2 |
| Revenue Growth, % | 0 | 3.19 | 21.26 | 4.35 | -11.2 | 4.4 | 4.4 | 4.4 | 4.4 | 4.4 |
| EBITDA | 478.2 | 552.2 | 619.5 | 654.7 | 633.3 | 618.8 | 646.0 | 674.4 | 704.1 | 735.1 |
| EBITDA, % | 17.68 | 19.78 | 18.3 | 18.53 | 20.19 | 18.9 | 18.9 | 18.9 | 18.9 | 18.9 |
| Depreciation | 55.0 | 56.2 | 77.8 | 88.3 | 90.1 | 76.7 | 80.1 | 83.6 | 87.3 | 91.2 |
| Depreciation, % | 2.03 | 2.01 | 2.3 | 2.5 | 2.87 | 2.34 | 2.34 | 2.34 | 2.34 | 2.34 |
| EBIT | 423.2 | 496.0 | 541.7 | 566.3 | 543.2 | 542.0 | 565.9 | 590.8 | 616.8 | 643.9 |
| EBIT, % | 15.64 | 17.77 | 16 | 16.03 | 17.32 | 16.55 | 16.55 | 16.55 | 16.55 | 16.55 |
| Total Cash | 1,634.7 | 2,109.3 | 2,536.6 | 3,167.9 | 3,051.4 | 2,605.9 | 2,720.6 | 2,840.2 | 2,965.2 | 3,095.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 386.2 | 380.4 | 242.9 | 470.6 | 334.7 | 386.9 | 403.9 | 421.7 | 440.2 | 459.6 |
| Account Receivables, % | 14.28 | 13.63 | 7.17 | 13.32 | 10.67 | 11.81 | 11.81 | 11.81 | 11.81 | 11.81 |
| Inventories | 281.4 | 268.2 | 313.9 | 336.2 | 273.5 | 311.2 | 324.9 | 339.2 | 354.1 | 369.7 |
| Inventories, % | 10.4 | 9.61 | 9.27 | 9.52 | 8.72 | 9.5 | 9.5 | 9.5 | 9.5 | 9.5 |
| Accounts Payable | 113.1 | 152.3 | 156.8 | 284.7 | 289.7 | 206.7 | 215.8 | 225.3 | 235.2 | 245.6 |
| Accounts Payable, % | 4.18 | 5.46 | 4.63 | 8.06 | 9.24 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 |
| Capital Expenditure | -46.4 | -45.4 | -65.1 | -75.0 | -248.4 | -100.2 | -104.6 | -109.3 | -114.1 | -119.1 |
| Capital Expenditure, % | -1.71 | -1.63 | -1.92 | -2.12 | -7.92 | -3.06 | -3.06 | -3.06 | -3.06 | -3.06 |
| Tax Rate, % | 15.52 | 15.52 | 15.52 | 15.52 | 15.52 | 15.52 | 15.52 | 15.52 | 15.52 | 15.52 |
| EBITAT | 360.7 | 417.6 | 459.1 | 484.7 | 458.8 | 459.9 | 480.1 | 501.3 | 523.3 | 546.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -185.3 | 486.7 | 568.1 | 376.0 | 504.2 | 263.5 | 434.0 | 453.1 | 473.0 | 493.8 |
| WACC, % | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 | 6.66 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,725.2 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 509 | |||||||||
| Terminal Value | 13,900 | |||||||||
| Present Terminal Value | 10,070 | |||||||||
| Enterprise Value | 11,795 | |||||||||
| Net Debt | -2,749 | |||||||||
| Equity Value | 14,544 | |||||||||
| Diluted Shares Outstanding, MM | 430 | |||||||||
| Equity Value Per Share | 33.80 |
Benefits You Will Receive
- Adjustable Forecast Inputs: Effortlessly modify key assumptions (growth %, profit margins, WACC) to evaluate various scenarios.
- Comprehensive Data: Mayinglong Pharmaceutical Group’s financial metrics pre-loaded to facilitate your analysis.
- Automated DCF Calculations: The template computes Net Present Value (NPV) and intrinsic value seamlessly.
- Tailorable and Professional: A sophisticated Excel model that conforms to your valuation requirements.
- Designed for Analysts and Investors: Perfect for assessing forecasts, validating strategies, and enhancing efficiency.
Key Features
- 🔍 Real-Life 600993SS Financials: Pre-filled historical and projected data for Mayinglong Pharmaceutical Group Co., LTD.
- ✏️ Fully Customizable Inputs: Adjust all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas that calculate the intrinsic value of Mayinglong using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize the valuation of Mayinglong instantly after modifying inputs.
- Scenario Analysis: Evaluate and compare outcomes based on different financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file for Mayinglong Pharmaceutical Group Co., LTD. (600993SS).
- Step 2: Take a look at the pre-filled financial data and forecasts for Mayinglong.
- Step 3: Adjust key parameters such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe how the DCF model refreshes in real-time as you change your assumptions.
- Step 5: Evaluate the results to inform your investment strategies.
Why Choose This Calculator for Mayinglong Pharmaceutical Group Co., LTD. (600993SS)?
- User-Friendly Design: Suitable for both novices and experienced users.
- Customizable Inputs: Effortlessly adjust assumptions to suit your analysis needs.
- Real-Time Valuation: Observe immediate updates to Mayinglong's valuation as you tweak inputs.
- Pre-Loaded Data: Includes Mayinglong’s actual financial information for swift analysis.
- Relied Upon by Experts: Utilized by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Investors: Accurately assess Mayinglong Pharmaceutical Group Co., LTD.’s (600993SS) fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for precise financial reporting and analysis for Mayinglong Pharmaceutical.
- Consultants: Efficiently customize the template for valuation reports tailored to clients in the pharmaceutical sector.
- Entrepreneurs: Understand the financial modeling strategies employed by leading pharmaceutical companies.
- Educators: Implement this resource as a teaching aid to illustrate valuation techniques in finance.
What the Template Contains
- Historical Data: Contains Mayinglong Pharmaceutical Group's past financials and baseline forecasts.
- DCF and Levered DCF Models: Comprehensive templates to assess the intrinsic value of Mayinglong Pharmaceutical Group.
- WACC Sheet: Pre-constructed calculations for Weighted Average Cost of Capital.
- Editable Inputs: Adjust key variables such as growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: An extensive overview of Mayinglong Pharmaceutical Group's financials.
- Interactive Dashboard: Dynamically visualize valuation outcomes and forecasts.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.